immunotherapy - International Biopharmaceutical Industry

news

Breakthroughs in Immunotherapy: Glycoproteins as Predictive Biomarkers for Therapeutic Response

Recent advancements in immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA4 have shown significant success in treating various advanced cancers and tumor type...

29 July 2024 news biomarkers | glycoprotein

Continue Reading →

news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...

30 May 2022 news blood | Bristol

Continue Reading →

news

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung ca...

13 May 2022 news cancer | Drug

Continue Reading →

news

Roche’s top immunotherapy prospect fails study in tough-to-treat lung cancer

Dive Brief: A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for a closel...

1 April 2022 news cancer | Drug

Continue Reading →

news

FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a ...

25 March 2022 news drugmakers | Eli Lilly

Continue Reading →

news

Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Dive Brief: Shares in Nektar Therapeutics fell by more than half Monday morning after the San Francisco biotech company and partner Bristol Myers Squibb disclosed ...

21 March 2022 news Biotech | Bristol Myers

Continue Reading →

news

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study su...

21 March 2022 news cancer | immunotherapy

Continue Reading →

news

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could h...

19 November 2021 news clinical trial | immunotherapy

Continue Reading →

news

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck's Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that's cleared for use in cervical cancer, the fourth ...

15 October 2021 news cervical cancer | clinical trial

Continue Reading →

news

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials haven't been com...

30 September 2021 news AstraZeneca | Bristol Myers Squibb

Continue Reading →